{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 124,
  "pageCount": 239,
  "prevPage": 123,
  "nextPage": 125,
  "slideType": "testimonial",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses highlighted text to emphasize key claims about market share loss and device failure.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/124",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-124",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "But the success was fleeting: \"almost all Nevro devices\" have since been explanted and doctors soured on Nevro.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-92d4f99572d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Another Medtronic employee - in charge of one of their largest spinal cord stimulation territories - offered ground level color on Nevro’s predicament. At launch in 2015, Nevro poached Medtronic’s senior rep and lured most of their “whale implanters” in the region to their device. But the success was fleeting: “almost all Nevro devices” have since been explanted and doctors soured on Nevro. By late 2016/early 2017, Nevro rapidly gave back the market share it gained in the region – mostly back to Medtronic, and some to Abbott.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9bda9fac-2b69-48b2-b0c2-20f5116b3cab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.06,
        "y": 0.6
      },
      "kind": "quote",
      "text": "In 2015/16 they came out with their guns and probably took, just from those two big accounts that I'm referring to, probably $4-million or $5-million. They had the cool new thing and the data from their pivotal HF10 trial was compelling. They had a good story, and everyone bought into the story. The docs trusted the rep who had been around for 20 years. Everyone was on board and thought it was the sexy new thing to offer their patients. Give or take the fall of 2016, our numbers started picking back up and then significantly in the spring of 2017. Medtronic had come out with a new algorithm to try to combat Nevro and we saw some good results, and we made significant changes to how we were talking to patients. It was good timing as Nevro was starting to see some failures and patients having different outcomes than what their study said.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f6c4add-276e-47fc-a29f-2599b86e1a22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.85
      },
      "kind": "quote",
      "text": "Of the $5-million or $6-million we lost to Nevro at the peak of their taking share, Abbott took one big chunk of that. They probably got $2-million, and we probably got back the rest. – Medtronic regional manager",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bca64fae-d7f4-4965-99eb-283bf31b391b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "quote",
      "text": "Since then, almost all Nevro devices have been either explanted, or they're trying to salvage a little bit with Omnia. But there really has been a significant decline in our market from their high frequency device. The doctors just didn't see the outcomes the studies were presenting. Their reps in town are trying to discuss the new technology and new research that they're touting, but it's been really slow to get a pickup from the physicians here. They continue to ask for a price premium and the surgeons in town aren't willing to pay for that.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb5e559b-bf0b-444c-8418-8d400d608217",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.31
      },
      "kind": "quote",
      "text": "In 2015, Nevro hired away the senior partner of our sales territory, which had quite an impact for 2016. Most of the big whale implanters in our territory made a full switch over to Nevro. That lasted, and really hurt us, for about a year.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e254d5c0-ea09-408c-9a22-bcb28d371072",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"In 2015, Nevro hired away the senior partner of our sales territory, which had quite an impact for 2016. Most of the big whale implanters in our territory made a full switch over to Nevro. That lasted, and really hurt us, for about a year.\" — Medtronic regional manager",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b340-94380e03a25a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0d4d9e2-534e-4cc6-aada-1842e659ee98",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.88,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "9. Nevro’s current predicament – a one-tick pony stuck in a ditch – and drivers of its ongoing growth collapse",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d84b270-0ea2-45b7-a339-5c43cc5f26cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e4fedca-a188-4c96-9a9a-66de4178e788",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}